How Resonant Link and Abbott Went from Impossible to a Path Forward in Nine Months

Resonant Link
June 12, 2023

It’s hard to make a good product even better. So much so that in 2006, Netflix offered $1 million to anyone who could make its movie recommendation engine better by just 10%. It took three years for someone to win. 

Luckily, when Abbott approached us about helping them fully implant their LVAD, it didn’t take three years to identify a way to safely and reliably wirelessly power their device. It took nine months.

Our partnership with Abbott began after decades of unsuccessful attempts to develop a Fully-Implanted Left-Ventricular Assist System (FILVAS) to improve patient outcomes and quality of life for those living with advanced heart failure. Fully-implanted systems had been sought by Abbott and others, but not realized due to the inefficiency of conventional wireless power, which heats up surrounding tissue too much.

A traditional LVAS or LVAD uses an implantable pump for hemodynamic support, connected through the abdomen by a wire called a driveline. To keep the heart pumping, LVAS requires continuous energy and communication through the driveline, which connects the device inside the body with an external controller and power source. This is both a technology barrier and a barrier to patient adoption, requiring significant lifestyle changes. Could there be a way for patients to have a safe, reliable, and efficient means of charging while living an untethered life, to its fullest? That’s the question Abbott posed to us.

The answer is yes and together with Abbott, we developed a FILVAS that places the pump, controller, and rechargeable system within the body. It combines our state of the art high-frequency power electronics, multi-layer self-resonant (MSRS) wireless coils, and electromagnetic shielding IP, with the Heartmate 3™ pump to deliver ~10 W of continuous power with a high misalignment tolerance to continuously run the pump and recharge the implanted battery even as the body moves. It does this while meeting strict thermal requirements, providing hope of a higher quality of life for millions living with heart failure.


For more information about Abbott’s in-development Fully-Implantable Left-Ventricular Assist System (FILVAS), you can read the full abstract in the ASAIO Journal.

Contact us today to discuss your medical device power needs.

Resonant Link
What’s Next
Prev text
Next text